GLP-1 Initiation Associated With Increase in Hypotensive Events in Patients With Hypertension - HCPLive

A new study presented at the Endocrine Society (ENDO) Annual Meeting 2026 reveals that initiating GLP-1 receptor agonist therapy in patients with pre-existing hypertension is associated with a statistically significant increase in hypotensive events, including fainting, dizziness, and falls. This finding from Northwestern Medicine researchers challenges the widely held view of GLP-1s as uniformly beneficial for cardiovascular health, introducing a critical safety nuance for a large, vulnerable patient population already managing high blood pressure with multiple medications. The implications are significant given the meteoric rise of GLP-1 drugs like Ozempic, Wegovy, and Mounjaro for diabetes and weight management, often lauded for their broader cardiovascular protections and modest blood pressure reductions. While GLP-1s are known to lower blood pressure, typically by 2-6 mmHg, through mechanisms like weight loss and increased sodium excretion, this new data spotlights a heightened risk in patients concurrently on multiple antihypertensive medications. The study tracked over 42,000 outpatients, noting the incidence of hypotensive events rose from 8.7% at baseline to 10.2% at 6 months and 14.3% at 12 months, with elderly patients and those with Type 2 Diabetes Mellitus disproportionately affected. Clinicians are now confronted with a complex balancing act, necessitating closer monitoring of blood pressure, especially during initial GLP-1 therapy and dose escalation, and potentially requiring adjustments to existing antihypertensive regimens to mitigate the risk of adverse events. This research underscores the need for individualized patient assessment, particularly for those with multiple comorbidities, and is likely to spur further investigation into specific patient subgroups and optimal management strategies to ensure the safe and effective use of these transformative medications.